Why the study?
Does pyrazinoylguanidine reduce serum triglycerides in ESRD patients undergoing maintenance hemodialysis?
Does pyrazinoylguanidine reduce serum triglycerides in ESRD patients undergoing maintenance hemodialysis?
Answers are grounded in this paper and cite their sources.
In a small pilot study of ESRD patients on hemodialysis, pyrazinoylguanidine significantly reduced serum triglycerides and was well tolerated.
Cardiovascular disease is the leading cause of mortality in end-stage renal disease (ESRD) patients receiving dialysis. In these patients, hypertriglyceridemia appears to increase the risk of accelerated atherosclerosis. The present placebo-controlled study evaluated prospectively lipid-lowering effects of pyrazinoylguanidine (PZG) in 6 ESRD patients undergoing maintenance hemodialysis. The design of the study entailed a placebo phase of 1 week followed by 3 weeks of PZG, 400 mg three times a day. Compared to placebo, PZG reduced serum triglycerides (PZG vs. placebo 370 +/- 171 vs. 414 +/- 182 mg/dl; p = 0.01). PZG also tended to decrease total cholesterol. In addition, PZG selectively lowered blood glucose in hyperglycemic patients. PZG was well tolerated; it did not interfere with hemodynamic parameters or alter liver function tests, nutritional parameters or dialysis clearance.
No takes yet. Share an insight, caveat, or question.
Ahsan et al. (1998) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: